Fu Tingyi,Gu Song.Research progress on liquid biopsy in neuroblastoma[J].Journal of Clinical Pediatric Surgery,2026,(01):92-95.[doi:10.3760/cma.j.cn101785-202302008]
液体活检在神经母细胞瘤中的应用研究进展
- Title:
- Research progress on liquid biopsy in neuroblastoma
- Keywords:
- Neuroblastoma; Liquid Biopsy; Circulating Tumor Cell; Circulating Tumor DNA; Exosomes; Surgical Procedures; Operative; Child
- 摘要:
- 神经母细胞瘤(neuroblastoma,NB)是发病率最高的儿童颅外恶性实体肿瘤。约50%的NB患者在确诊时已处于高危状态,有较高的复发及死亡风险,因此NB的早期诊断、肿瘤负荷监测及治疗、预后评估至关重要。目前NB的诊断仍然主要依靠组织学病理结果,需要进行活检/切除活检或骨髓穿刺等侵入性操作,由于肿瘤的高度异质性,易出现漏诊、误诊。液体活检是一种检验体液标本中细胞及核酸的新兴检测手段,可减少侵入性操作,克服肿瘤异质性,为促进NB早期诊断、动态监测、疗效评估提供可能。本综述将介绍液体活检在儿童神经母细胞瘤中应用的研究进展。
- Abstract:
- Neuroblastoma (NB) is the most common extracranial malignant solid tumor in children.At the time of diagnosis,about 50% of NB patients are already at high risk and face elevated risks of relapse and mortality.Therefore,early diagnosis,tumor burden assessment,and evaluation of treatment and prognosis are crucial.Currently,NB diagnosis relies largely on histopathological findings,necessitating biopsies or bone marrow aspiration-both invasive procedures.Moreover,the significant heterogeneity of NB can lead to missed or inaccurate diagnoses.Liquid biopsy is an emerging technique for detecting cells and nucleic acids in bodily fluids,potentially reducing the need for invasive procedures and overcoming tumor heterogeneity.It also holds promise for enabling early diagnosis,real-time monitoring,and efficacy evaluation in NB.This review summarizes the research progress on the application of liquid biopsy in pediatric neuroblastoma.
参考文献/References:
[1] 张梅慧,姜大朋.先天性神经母细胞瘤发病机制与临床特点的研究进展[J].临床小儿外科杂志,2022,21(2):141-145.DOI:10.3760/cma.j.cn101785-202105045-008. Zhang MH,Jiang DP.Pathogenesis and clinical characteristics of congenital neuroblastoma[J].DOI:10.3760/cma.j.cn101785-202105045-008.
[2] Park JR,Eggert A,Caron H.Neuroblastoma:biology,prognosis,and treatment[J].Hematol Oncol Clin North Am,2010,24(1):65-86.DOI:10.1016/j.hoc.2009.11.011.
[3] Poulet G,Massias J,Taly V.Liquid biopsy:general concepts[J].Acta Cytol,2019,63(6):449-455.DOI:10.1159/000499337.
[4] Siravegna G,Marsoni S,Siena S,et al.Integrating liquid biopsies into the management of cancer[J].Nat Rev Clin Oncol,2017,14(9):531-548.DOI:10.1038/nrclinonc.2017.14.
[5] Liu SY,Wen FQ.Recent clinical research on the application of liquid biopsy in neuroblastoma[J].Chin J Contemp Pediatr,2022,24(3):339-344.DOI:10.7499/j.issn.1008-8830.2112120.
[6] Merugu S,Chen LD,Gavens E,et al.Detection of circulating and disseminated neuroblastoma cells using the ImageStream flow cytometer for use as predictive and pharmacodynamic biomarkers[J].Clin Cancer Res,2020,26(1):122-134.DOI:10.1158/1078-0432.CCR-19-0656.
[7] Seeger RC,Reynolds CP,Gallego R,et al.Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma:a Children’s Cancer Group Study[J].J Clin Oncol,2000,18(24):4067-4076.DOI:10.1200/JCO.2000.18.24.4067.
[8] Kuroda T,Morikawa N,Matsuoka K,et al.Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma[J].J Pediatr Surg,2008,43(12):2182-2185.DOI:10.1016/j.jpedsurg.2008.08.046.
[9] Kojima M,Harada T,Fukazawa T,et al.Single-cell DNA and RNA sequencing of circulating tumor cells[J].Sci Rep,2021,11(1):22864.DOI:10.1038/s41598-021-02165-7.
[10] Kojima M,Harada T,Fukazawa T,et al.Single-cell next-generation sequencing of circulating tumor cells in patients with neuroblastoma[J].Cancer Sci,2023,114(4):1616-1624.DOI:10.1111/cas.15707.
[11] Wei M,Ye MJ,Dong KR,et al.Circulating tumor DNA in neuroblastoma[J].Pediatr Blood Cancer,2020,67(10):e28311.DOI:10.1002/pbc.28311.
[12] Kahana-Edwin S,Cain LE,McCowage G,et al.Neuroblastoma molecular risk-stratification of DNA copy number and ALK genotyping via cell-free circulating tumor DNA profiling[J].Cancers (Basel),2021,13(13):3365.DOI:10.3390/cancers13133365.
[13] Lodrini M,Graef J,Thole-Kliesch TM,et al.Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma[J].Clin Cancer Res,2022,28(9):1809-1820.DOI:10.1158/1078-0432.CCR-21-3716.
[14] van Zogchel LMJ,van Wezel EM,van Wijk J,et al.Hypermethylated RASSF1A as circulating tumor DNA marker for disease monitoring in neuroblastoma[J].JCO Precis Oncol,2020,4:291-306.DOI:10.1200/PO.19.00261.
[15] Bosse KR,Giudice AM,Lane MV,et al.Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma[J].Cancer Discov,2022,12(12):2800-2819.DOI:10.1158/2159-8290.CD-22-0287.
[16] Dai J,Su YZ,Zhong SY,et al.Exosomes:key players in cancer and potential therapeutic strategy[J].Signal Transduct Target Ther,2020,5(1):145.DOI:10.1038/s41392-020-00261-0.
[17] Kalluri R.The biology and function of exosomes in cancer[J].J Clin Invest,2016,126(4):1208-1215.DOI:10.1172/JCI81135.
[18] Yu D,Li YX,Wang MY,et al.Exosomes as a new frontier of cancer liquid biopsy[J].Mol Cancer,2022,21(1):56.DOI:10.1186/s12943-022-01509-9.
[19] Zhou YJ,Zhang Y,Gong H,et al.The role of exosomes and their applications in cancer[J].Int J Mol Sci,2021,22(22):12204.DOI:10.3390/ijms222212204.
[20] Papadopoulos D,Solvie D,Baluapuri A,et al.MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts[J].Mol Cell,2022,82(1):159-176.e12.DOI:10.1016/j.molcel.2021.11.002.
[21] Ma J,Xu M,Yin MZ,et al.Exosomal hsa-miR199a-3p promotes proliferation and migration in neuroblastoma[J].Front Oncol,2019,9:459.DOI:10.3389/fonc.2019.00459.
[22] Neviani P,Wise PM,Murtadha M,et al.Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms[J].Cancer Res,2019,79(6):1151-1164.DOI:10.1158/0008-5472.CAN-18-0779.
[23] Challagundla KB,Wise PM,Neviani P,et al.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy[J].J Natl Cancer Inst,2015,107(7):djv135.DOI:10.1093/jnci/djv135.
[24] Nakata R,Shimada H,Fernandez GE,et al.Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells[J].J Extracell Vesicles,2017,6(1):1332941.DOI:10.1080/20013078.2017.1332941.
相似文献/References:
[1]郭春宝,王珊,金先庆,等.Cochrane系统评价方法对神经母细胞瘤分子与生物标记物的Meta分析[J].临床小儿外科杂志,2008,7(01):2.
[2]未德成,王忠荣,张燕敏,等.脂氧合酶抑制剂NDGA对人神经母细胞瘤SK-N-SH细胞生物学特性的影响[J].临床小儿外科杂志,2008,7(01):3.
[3]陈新让,王家祥,余捷凯,等.基于支持向量机神经母细胞瘤血清蛋白质标记物的检测及临床应用[J].临床小儿外科杂志,2008,7(02):12.
[4]罗远建,金科,甘青,等.儿童神经母细胞瘤的影像学表现[J].临床小儿外科杂志,2007,6(02):22.
[5]李昆昆 金先庆 牟廷刚 陈建飞 赵利华 丁雄辉 孙艳辉 王士奇. ATRA耐药基因HA117相关蛋白在四种恶性肿瘤的表达及临床意义[J].临床小儿外科杂志,2011,10(04):250.
[J].Journal of Clinical Pediatric Surgery,2011,10(01):250.
[6]沙永亮 吴晔明. 化疗及非化疗组神经母细胞瘤干细胞标志物的表达及意义[J].临床小儿外科杂志,2011,10(04):254.
[J].Journal of Clinical Pediatric Surgery,2011,10(01):254.
[7]刘涛 韩英 祝秀丹 王焕民 秦红 邹焱. Wnt—5a基因在神经母细胞瘤中的表达及意义[J].临床小儿外科杂志,2011,10(05):333.
[J].Journal of Clinical Pediatric Surgery,2011,10(01):333.
[8]顾 涛 鹿洪亭 董 蒨.Kai1/CD82表达水平与神经母细胞瘤转移的关系探讨[J].临床小儿外科杂志,2013,12(02):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
GU Tao,LU Hong-ting,DONG Qian.The relationship between Kai1/CD82 expression and metastasis of neuroblastoma[J].Journal of Clinical Pediatric Surgery,2013,12(01):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
[9]邢莉莉,吴晔明,张弛.熊果酸对神经母细胞瘤细胞增殖凋亡及 MYCN表达的影响[J].临床小儿外科杂志,2013,12(03):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
XING Li li,WU Ye ming,ZHANG Chi..Ursolic acid effects proliferation、apoptosis and MYCN expression of neuroblastoma cell[J].Journal of Clinical Pediatric Surgery,2013,12(01):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
[10]张雁冰 刘朝阳 卢其 周小渔. RNA干扰对神经母细胞瘤细胞VEGFA的ｍRNA表达的影响[J].临床小儿外科杂志,2013,12(06):471.
备注/Memo
收稿日期:2023-2-6。
基金项目:上海申康医院发展中心(shdc2020cr2061b)
通讯作者:顾松,Email:gusong@shsmu.edu.cn